- Home
- VYNE vs DRCT Comparison
VYNE vs DRCT Comparison
Compare VYNE & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- DRCT
- Stock Information
- Founded
- VYNE 2003
- DRCT 2018
- Country
- VYNE United States
- DRCT United States
- Employees
- VYNE N/A
- DRCT N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- DRCT Computer Software: Programming Data Processing
- Sector
- VYNE Health Care
- DRCT Technology
- Exchange
- VYNE Nasdaq
- DRCT Nasdaq
- Market Cap
- VYNE 7.9M
- DRCT 8.8M
- IPO Year
- VYNE 2018
- DRCT 2022
- Fundamental
- Price
- VYNE $0.43
- DRCT $0.29
- Analyst Decision
- VYNE Buy
- DRCT Strong Buy
- Analyst Count
- VYNE 2
- DRCT 1
- Target Price
- VYNE $8.00
- DRCT $6.00
- AVG Volume (30 Days)
- VYNE 3.1M
- DRCT 1.8M
- Earning Date
- VYNE 11-06-2025
- DRCT 11-11-2025
- Dividend Yield
- VYNE N/A
- DRCT N/A
- EPS Growth
- VYNE N/A
- DRCT N/A
- EPS
- VYNE N/A
- DRCT N/A
- Revenue
- VYNE $476,000.00
- DRCT $36,459,000.00
- Revenue This Year
- VYNE N/A
- DRCT $16.81
- Revenue Next Year
- VYNE N/A
- DRCT $35.28
- P/E Ratio
- VYNE N/A
- DRCT N/A
- Revenue Growth
- VYNE N/A
- DRCT N/A
- 52 Week Low
- VYNE $0.28
- DRCT $0.28
- 52 Week High
- VYNE $4.30
- DRCT $6.59
- Technical
- Relative Strength Index (RSI)
- VYNE 60.37
- DRCT 33.87
- Support Level
- VYNE $0.32
- DRCT $0.29
- Resistance Level
- VYNE $0.35
- DRCT $0.39
- Average True Range (ATR)
- VYNE 0.02
- DRCT 0.05
- MACD
- VYNE 0.02
- DRCT -0.00
- Stochastic Oscillator
- VYNE 84.88
- DRCT 4.72
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.